The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid

Background Lapatinib is a small-molecule tyrosine kinase inhibitor of human epidermal receptor 2 (HER2) and EGFR that has currently been approved for the treatment of HER2-positive advanced and metastatic breast cancer (BC). The ATP-binding cassette (ABC) family of transporters includes P-glycoprote...

Descripción completa

Detalles Bibliográficos
Autores principales: Karbownik, Agnieszka, Sobańska, Katarzyna, Płotek, Włodzimierz, Grabowski, Tomasz, Klupczynska, Agnieszka, Plewa, Szymon, Grześkowiak, Edmund, Szałek, Edyta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211195/
https://www.ncbi.nlm.nih.gov/pubmed/31177402
http://dx.doi.org/10.1007/s10637-019-00806-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211195/
https://www.ncbi.nlm.nih.gov/pubmed/31177402
http://dx.doi.org/10.1007/s10637-019-00806-3

Ejemplares similares